Subscribe

Clínica Baviera, S.A. (CBAV.MC)

EUR57.60 +1.00 (+1.77%)
ES BME Healthcare Medical - Diagnostics & Research
Address Paseo de la Castellana 20 28046
Madrid, ES
CEO Eduardo Baviera Sabater
Website clinicabaviera.com
IPO 2007-04-03
ISIN ES0119037010

Explore sections of this company profile

Description

Clínica Baviera, S.A., a healthcare provider, manages a substantial chain of ophthalmological centers. This organization dedicates itself to the comprehensive diagnosis, therapeutic intervention, and continuous monitoring of diverse ocular conditions. Its facilities offer a wide range of specialized services, addressing issues such as myopia, hyperopia, astigmatism, presbyopia, cataracts, retinal disorders, pediatric eye ailments, glaucoma, strabismus (squint), corneal diseases, neuro-ophthalmology, lacrimal duct problems (vías lagrimales), and oculoplastic procedures. Operating around 90 sites, the company's geographical footprint extends across Spain, Germany, Austria, and Italy. The corporate headquarters are located in Madrid, Spain.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR57.60 +1.00 (+1.77%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3.8K
Beta
0.76
Float Shares
2.40M
Free Float %
15.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-2.36% +7.81% +3.94% +11.11% +28.32% +16.70% +40.78% +216.94% +294.56% +700.00% +146.81%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
57.60
DCF (Unlevered) 36.53 -36.6%
DCF (Levered) 43.86 -23.9%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
6.04
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
8 / 10
Strong MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Diagnostics & Research: +7.9%
    +14.9% ★ Q1'26: +8.4% (vs Q1'25)
  • ✓
    EPS growth Medical - Diagnostics & Research: +30.8%
    +4.5% Q1'26: +15.0% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%
    +17.0% Q1'26: +20.4% (vs Q1'25)
  • ✓
    EBIT margin Medical - Diagnostics & Research: +9.6%
    +20.1% ★ Q1'26: +22.7% (vs Q1'25)
  • ✓
    ROIC Medical - Diagnostics & Research: +5.2%
    +33.3% ★ Q1'26: +44.8% (vs Q1'25)
  • ✗
    Share dilution Medical - Diagnostics & Research: 0.0%
    +2.3% Q1'26: +0.2% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×
    0.82× Q1'26: 0.65× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.77) × ERP
WACC = 93% × Ke + 7% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 36.53 Current price: 57.60
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
85.53M
est: 85.00M (+0.6%)
91.57M
est: 92.00M (-0.5%)
99.88M
est: 101.00M (-1.1%)
109.29M
est: 93.00M (+17.5%)
124.33M
est: 118.80M (+4.7%)
122.63M
est: 123.33M (-0.6%)
172.73M
est: 136.56M (+26.5%)
198.45M
est: 197.00M (+0.7%)
224.92M
est: 209.00M (+7.6%)
262.65M
est: 268.30M (-2.1%)
301.78M
est: 296.95M (+1.6%)
330.35M
330.35M – 330.35M
+11.2% YoY
363.70M
363.70M – 363.70M
+10.1% YoY
397.80M
397.80M – 397.80M
+9.4% YoY
EBITDA
11.88M
est: 24.96M (-52.4%)
16.51M
est: 27.02M (-38.9%)
18.02M
est: 29.66M (-39.2%)
21.93M
est: 27.31M (-19.7%)
31.53M
est: 34.89M (-9.6%)
34.27M
est: 36.22M (-5.4%)
53.49M
est: 40.10M (+33.4%)
56.15M
est: 57.85M (-2.9%)
67.22M
est: 61.37M (+9.5%)
78.11M
est: 78.82M (-0.9%)
84.54M
est: 87.24M (-3.1%)
97.05M
97.05M – 97.05M
+11.2% YoY
106.85M
106.85M – 106.85M
+10.1% YoY
116.87M
116.87M – 116.87M
+9.4% YoY
EBIT
7.03M
est: 17.78M (-60.5%)
11.61M
est: 19.24M (-39.7%)
13.63M
est: 21.12M (-35.5%)
16.97M
est: 19.45M (-12.7%)
18.32M
est: 24.84M (-26.3%)
20.72M
est: 25.79M (-19.7%)
39.39M
est: 28.56M (+37.9%)
41.10M
est: 41.20M (-0.2%)
50.22M
est: 43.71M (+14.9%)
57.21M
est: 57.81M (-1.0%)
60.54M
est: 63.98M (-5.4%)
71.18M
71.18M – 71.18M
+11.2% YoY
78.36M
78.36M – 78.36M
+10.1% YoY
85.71M
85.71M – 85.71M
+9.4% YoY
Net Income
4.88M
est: 3.91M (+24.9%)
7.91M
est: 5.05M (+56.8%)
9.77M
est: 6.67M (+46.4%)
11.83M
12.79M
est: 13.18M (-3.0%)
13.94M
est: 14.54M (-4.1%)
27.39M
est: 15.97M (+71.5%)
29.52M
est: 27.67M (+6.7%)
35.97M
est: 28.32M (+27.0%)
40.21M
est: 39.44M (+1.9%)
42.94M
est: 42.94M (0.0%)
47.10M
47.10M – 47.10M
+9.7% YoY
55.09M
55.09M – 55.09M
+17.0% YoY
62.99M
62.99M – 62.99M
+14.4% YoY
SGA
12.96M
est: 11.05M (+17.3%)
13.52M
est: 11.96M (+13.1%)
16.75M
est: 13.13M (+27.6%)
16.50M
est: 12.09M (+36.5%)
19.12M
est: 15.44M (+23.8%)
14.96M
est: 16.03M (-6.7%)
23.21M
est: 17.75M (+30.8%)
28.21M
est: 25.60M (+10.2%)
26.16M
est: 27.16M (-3.7%)
35.46M
est: 28.32M (+25.2%)
—
est: 31.35M (-100.0%)
34.87M
34.87M – 34.87M
+11.2% YoY
38.40M
38.40M – 38.40M
+10.1% YoY
42.00M
42.00M – 42.00M
+9.4% YoY
EPS
0.30
est: 0.24 (+25.0%)
0.49
est: 0.31 (+58.1%)
0.60
est: 0.41 (+46.3%)
0.73
0.78
est: 0.81 (-3.7%)
0.86
est: 0.89 (-3.7%)
1.68
est: 0.98 (+71.2%)
1.81
est: 1.70 (+6.5%)
2.21
est: 1.74 (+27.0%)
2.47
est: 2.37 (+4.2%)
2.58
est: 2.58 (+0.0%)
2.83
2.83 – 2.83
+9.7% YoY
3.31
3.31 – 3.31
+17.0% YoY
3.79
3.79 – 3.79
+14.4% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-28 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-27 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-26 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-25 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-22 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-21 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-20 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-19 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-18 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-15 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-14 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-13 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-12 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-11 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-05-08 B+ 3/5 4/5 5/5 5/5 1/5 3/5 1/5
2026-05-07 B+ 3/5 4/5 5/5 5/5 1/5 3/5 1/5
2026-05-06 B+ 3/5 4/5 5/5 5/5 1/5 3/5 1/5
2026-05-05 B+ 3/5 4/5 5/5 5/5 1/5 3/5 1/5
2026-05-04 B+ 3/5 4/5 5/5 5/5 1/5 3/5 1/5
2026-04-30 B+ 3/5 4/5 5/5 5/5 1/5 3/5 1/5
2026-04-29 B+ 3/5 4/5 5/5 5/5 1/5 3/5 1/5
2026-04-28 B+ 3/5 4/5 5/5 5/5 1/5 3/5 1/5
2026-04-27 B+ 3/5 4/5 5/5 5/5 1/5 3/5 1/5
2026-04-24 B+ 3/5 4/5 5/5 5/5 1/5 3/5 1/5
2026-04-23 B+ 3/5 4/5 5/5 5/5 1/5 3/5 1/5
2026-04-22 B+ 3/5 4/5 5/5 5/5 1/5 3/5 1/5
2026-04-21 B+ 3/5 4/5 5/5 5/5 1/5 3/5 1/5
2026-04-20 B+ 3/5 4/5 5/5 5/5 1/5 3/5 1/5
2026-04-17 B+ 3/5 4/5 5/5 5/5 1/5 3/5 1/5
2026-04-16 B+ 3/5 4/5 5/5 5/5 1/5 3/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
64.51M
OE per share TTM
3.96
Owner's Yield
6.17%
Maintenance CapEx ratio
60.16%
Maint CapEx / Avg PPE
47.7%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
35.5K
Shares Outstanding
16.02M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Eduardo Baviera Sabater MD, Chief Executive Officer & Executive Director 200.0K male
Julio Baviera Sabater President 43.3K male
Antonio Peral Ortiz de la Torre Company Secretary — male
Virgilio Leal Espí Chief Financial Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Diagnostics & Research